Roberto Baldelli

Dr. Roberto Baldelli


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
EVEleonora Vitali
Eleonora Vitali
IBIlena Boemi
Ilena Boemi
GTGiulia Tarantola
Giulia Tarantola
SPSara Piccini
Sara Piccini
AZAlessandro Zerbi
Alessandro Zerbi
Lania Andrea Gerardo AntonioLania Andrea Gerardo Antonio
Lania Andrea Gerardo Antonio
Introduction: Treatment options for neuroendocrine tumors (NETs) are rarely curative, as NETs frequently show resistance to medical therapy. The use of everolimus, an mTOR inhibitor, is limited by the development of resistance, probably due to the activation of Akt signaling. In this context, the antidiabetic drug metformin is able to inhibit mTOR, providing a rationale for the use of metformin and everolimus in combination. Methods: We investigated the effects of the metformin and everolimus combination on NET cell proliferation, apoptosis, colony formation, cell viability, NET spheroids growth and the involvement of the Akt and mTOR pathways, and also developed everolimus-resistant NET cells to further study this combination. Results: Metformin and everolimus in combination are more effective than monotherapy in inhibiting pancreatic NET (PAN-NET) cell proliferation (−71% ± 13%, p < 0.0001 vs. basal), whereas no additive effects were observed on pulmonary neuroendocrine tumor (PNT) cell proliferation. The combinatorial treatment is more effective than monotherapy in inhibiting colony formation, cell viability, NET spheroids growth rate and mTOR phosphorylation in both NET cell lines. In a PAN-NET cell line, metformin did not affect Akt phosphorylation; conversely, it significantly decreased Akt phosphorylation in a PNT cell line. Using everolimus-resistant NET cells, we confirmed that metformin maintained its effects, acting by two different pathways: Akt-dependent or independent, depending on the cell type, with both leading to mTOR suppression. Conclusions: Considering the promising effects of the everolimus and metformin combination in NET cells, our results provide a rationale for its use in NET patients.

13 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VVValentina Di Vito
Valentina Di Vito
GVGabriele Veroi
Gabriele Veroi
LRLaura Rizza
Laura Rizza
FRFrancesca Rota Rota
Francesca Rota Rota
ABAndrea Baiocchini
Andrea Baiocchini
RBRoberto Baldelli
Roberto Baldelli
Background: Ovarian neuroendocrine neoplasms (O-NENs) are extremely rare, representing less than 1% of all ovarian neoplasms and under 5% of all neuroendocrine tumors (NETs). They encompass two primary histological subtypes: well-differentiated carcinoids and poorly differentiated neuroendocrine carcinomas, which display distinct biological behaviors and prognoses. The ovary can also be a site of metastasis from extra-ovarian NETs. Owing to their rarity, clinical management lacks standardization, and diagnosis is often incidental following surgery for presumed epithelial ovarian neoplasms. Objectives: This review aims to provide an updated synthesis of current evidence on the epidemiology, pathogenesis, clinical presentation, diagnosis, treatment strategies, and prognosis of O-NENs, highlighting unmet clinical needs. Methods: A literature search was performed on PubMed for the years 2014–2024 using the keywords: “ovarian neuroendocrine tumor”, “ovarian neuroendocrine neoplasm”, “ovarian neuroendocrine carcinoma”, and “ovarian carcinoid”. Only articles published in English were considered. Given the rarity of the disease, in addition to meta-analyses and systematic reviews, relevant case reports and case series were also included to provide a comprehensive clinical picture, yielding 32 eligible articles. Results: Evidence indicates that O-NENs remain understudied, with most data derived from case reports and small series. Clinical presentations vary from asymptomatic masses to hormone-related syndromes, often mimicking other ovarian pathologies. Diagnostic work-up typically follows the same protocol as epithelial ovarian cancer, with the neuroendocrine nature only recognized postoperatively. Treatment strategies are empirical and largely extrapolated from extra-ovarian NETs due to the absence of specific guidelines. Prognosis varies widely depending on histotype, stage, and secretory activity. Conclusions: O-NENs pose significant diagnostic and therapeutic challenges due to their rarity and heterogeneity. Greater clinical awareness, multidisciplinary management, and multicenter research are essential to establish evidence-based protocols and improve patient outcomes.

Verified
Journal Article
Open access
PDF file
Marta CamiciMarta Camici
Marta Camici
MFMarta Franco
Marta Franco
LTLorenzo Talamanca
Lorenzo Talamanca
JPJESSICA PAULICELLI
JESSICA PAULICELLI
LSLiliana Scarnecchia
Liliana Scarnecchia
AAAndrea Antinori
Andrea Antinori
This prospective, single-center, case-control study investigated circulating autoantibodies (AAbs) targeting G protein-coupled receptors (GPCRs) in Long COVID (LC) patients to identify potential diagnostic biomarkers and therapeutic targets. Fifteen participants were enrolled at the LC clinic in Rome: eleven with severe LC—defined as >4 persistent symptoms (fatigue, cognitive impairment, poor exercise tolerance, dyspnea, arthralgia, or dysautonomic manifestations) >3 months post-infection—and four asymptomatic post-COVID (APC) individuals. Fatigue was assessed using the Fatigue Assessment Scale (FAS ≥ 22; severe ≥ 35). Auto-Abs against AT1R, endothelin receptor A, adrenergic (α1, α2, β1, β2), and muscarinic (M1–M5) receptors were quantified, along with blood cortisol and ACTH levels. SARS-CoV-2-specific T-cell responses to Spike and Nucleocapsid proteins were evaluated by ELISpot assay. In our small cohort, LC patients were younger, had fewer comorbidities (p = 0.03), fewer vaccine doses (p = 0.03), and higher FAS scores (33 vs. 12; p = 0.001). Mean GPCR AAbs levels were higher in LC than in APC (8.88 vs. 5.45 Units/mL; p = 0.17), indicating a coherent autoimmune signature in LC that correlates with symptom development. Morning cortisol was lower in LC (12.7 vs. 17 mg/dL; p = 0.01), and T-cell responses tended to be weaker. These findings suggest GPCR AAbs may serve as biomarkers and therapeutic targets for a subset of patients, guiding diagnosis and treatments with IV immunoglobulin or immunoadsorption.

4 June 2024 in L'Endocrinologo
Verified
Journal Article
Closed access
PDF file
RBRoberto Baldelli
Roberto Baldelli
RFRiccardo De Fata
Riccardo De Fata
RBRaffaella Buzzetti
Raffaella Buzzetti
PZPaolo Zuppi
Paolo Zuppi
RGRocio Garcia-Carbonero
Rocio Garcia-Carbonero
ASAnna La Salvia
Anna La Salvia

11 November 2025 in L'Endocrinologo
Verified
Journal Article
Closed access
PDF file
VVValentina Di Vito
Valentina Di Vito
GVGabriele Veroi
Gabriele Veroi
FCFiammetta Cipriani
Fiammetta Cipriani
NVNorman Veccia
Norman Veccia
ABAndrea Baiocchini
Andrea Baiocchini
RBRoberto Baldelli
Roberto Baldelli

8 August 2022 in L'Endocrinologo
Verified
Journal Article
Closed access
PDF file
SCStefano Colangelo
Stefano Colangelo
MFMarta Franco
Marta Franco
PZPaolo Zuppi
Paolo Zuppi
RBRoberto Baldelli
Roberto Baldelli